Navigation Links
Elekta Radiosurgery Solutions are Creating New Possibilities for the Most Challenging Cases of the Head And Body
Date:4/30/2009

Latest radiosurgery solutions from Elekta discussed at the 2009 AANS Meeting

ATLANTA, April 30 /PRNewswire/ -- At the 2009 American Association of Neurological Surgeons (AANS) Annual Meeting, May 4-6 at the San Diego Convention Center, Elekta customers and personnel will discuss how Elekta's latest line of stereotactic treatment solutions is addressing some of the most challenging cases facing neurosurgeons and oncologists today.

Local Control of Brain Mets

Recent studies estimate that 25 percent of all cancer patients - particularly patients with melanoma, lung cancer, or advanced breast cancer - will develop brain metastases and require whole brain therapy. While whole brain radiotherapy is a treatment option, it also subjects healthy brain tissue to radiation dosages that may have negative side affects or limit the amount of therapeutic dose that can be applied in the event of a re-occurrence. In addition, whole brain radiation requires an interruption in the chemotherapy treatments that are so important to maintaining tumor control.

Dr. Christopher M. Duma, Neurological Surgeon at Hoag Memorial Hospital Presbyterian in Newport Beach, California will discuss the use of Leksell Gamma Knife(R) Perfexion(TM) to treat multiple brain metastases in a single session. Gamma Knife(R) surgery always has been especially good at treating very small targets with little or no damage to healthy tissue; but Perfexion is able to treat several targets faster and more efficiently making it a viable option of patients with brain metastases. The result is a fast and effective treatment for brain metastases that is easier on the patient, reduces the damage to healthy tissue that may limit future treatment options, and allows for concomitant chemotherapy for optimum primary tumor control.

Stereotactic Radiosurgery of the Spine

While Gamma Knife(R) surgery was initially invented to treat inoperable cancers and disorders in the brain, now the kind of stereotactic treatment precision established by Elekta can be applied to extra-cranial tumors. Today, the latest advancements in image guidance and dynamic arc delivery pioneered by Elekta combined with Leksell-quality fixation options support Stereotactic Radiosurgery (SRS) and Stereotactic Radiation Therapy (SRT) anywhere in the body to deliver optimal dose to the tumor, while protecting vital organs like the spinal cord.

Dr. Peter C. Gerszten, Associate Professor of Neurological Surgery and Radiation Oncology at the University of Pittsburgh Medical Center and co-editor of Spine Radiosurgery, will discuss the use of Elekta Axesse(TM) to perform stereotactic radiosurgery for spine and paraspinal lesions. According to Dr. Gerszten, "Axesse is fully optimized for SRS and SRT and therefore well suited for spine radiosurgery, providing patients a fast, safe, and effective treatment alternative or as an adjunct to open surgical intervention."

More than sixty years ago, Professor Lars Leksell developed a three-coordinate head frame and revolutionized the field of stereotaxy. Twenty years later he conceived of replacing the surgical precision of the neurosurgeon with precisely targeted radiation, and invented the field of stereotactic radiosurgery (SRS). Today, Leksell Gamma Knife(R) Perfexion(TM) is still the benchmark upon which all other SRS methods are measured; Perfexion equipped with Extend Program*(TM) is capable of treating cancers of the head and neck and lesions previously unsuitable for Gamma Knife surgery; And Elekta Axesse(TM) supports SRS and SRT anywhere in the body making it a versatile cross-over solution for neurosurgery and oncology.

According to President and CEO of Elekta North America, Joseph K. Jachinowski, "Since its very foundation, Elekta has sought to develop technology that allowed practitioners to achieve specific clinical objectives. Today Elekta Neuroscience is still developing technology to address the most challenging cases in neurosurgery and oncology, creating new treatment possibilities that are redefining what we call, human care."

*Extend requires 510(k) review and is not yet commercially available in the U.S.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mass Financial Corp. Launches Lawsuit Against Elekta AB, Seeks Substantial Damages
2. Xoft Signs Sales Development Agreement With Elekta
3. Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement
4. Elekta Launches Web-based Virtual Clinic, Offers Better Understanding of Radiotherapy Solutions for the Treatment of Cancer
5. Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting
6. CMS, Inc., an Elekta Company, Receives FDA 510(k) Clearance for Atlas-Based Autosegmentation Software
7. Elekta Finds New Interest in Leasing Solutions as Hospitals Debate Capital Purchases
8. Hospitals Turn to Vendors Like Elekta for Help in Squeezing Most From Existing Technologies
9. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network
10. Elekta Sponsors All Are Our Heroes to Raise Cancer Awareness
11. Elekta Contract Provides MAGNET Cooperative Access to Leading Radiation Therapy Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology: